About Deciphex
Deciphex is transforming pathology through AI-powered digital platforms and a global network of expert pathologists. The company addresses critical shortages in pathology resources by enabling remote, accurate diagnostics at scale. Deciphex operates through three integrated brands: Patholytix, an AI-powered digital platform streamlining regulated research workflows for drug safety; Diagnexia, a global network of subspecialty pathologists connected through a digital platform providing 24/7 diagnostic services; and an integrated platform accelerating end-to-end drug development. The company serves 9 out of 10 top pharmaceutical companies, helping accelerate preclinical drug development while reducing pathologist review time by over 20%. In the NHS, Deciphex has reduced pathology wait times from 2 months to 2 days through AI-powered platforms that integrate directly with NHS systems. The company maintains the world's largest repository of digital slides and is pioneering pathologist-centric foundation models. Deciphex collaborates with leading organizations including Novartis, Charles River Laboratories, and NHS Trusts to advance AI in pathology. The company is committed to democratizing access to high-quality pathology, including pro-bono support in underserved areas, while ensuring every patient worldwide receives accurate diagnoses and effective treatments promptly.
Mission & Story
Mission
Deciphex's mission is to leverage the combined power of AI and a global network of expert pathologists to deliver faster, more accurate diagnostics, reducing diagnostic delays and driving improvements in patient care and drug discovery.
Clinical Focus
Medical conditions and clinical areas addressed by Deciphex.
Who It Serves
Milestones & Awards
Recent Milestones
Secured €15M venture debt facility from Claret Capital Partners (October 2025). Achieved full UKAS accreditation for Oxford Histopathology Laboratory and Digital Pathology Services (November 2025). Developed Foresight suite of pre-trained AI models with Charles River Laboratories.
Awards & Recognition
UKAS accreditation for end-to-end histopathology service
Key Partnerships
Social & Media
Follow on
Latest Updates
Diagnexia Achieves Full UKAS Accreditation for Oxford Histopathology Laboratory and Digital Pathology Services
8mo ago
Diagnexia Achieves Full UKAS Accreditation for Oxford Histopathology Laboratory and Digital Pathology Services
8mo ago
Deciphex Secures €15M Venture Debt Funding from Claret Capital Partners to Accelerate Growth
9mo ago
AI Has Arrived in Pathology, And It’s Seeing What We Couldn’t
1y ago
Rewriting the Rules of Pathology: Diagnexia's Shift from Service Provider to Vital Partner
1y ago
Company Details
- Headquarters
- Dublin, Ireland
Work here?
Claim this listing to update company information and connect with our audience.
Claim This ListingSecurity & Compliance
Official Sources
Similar Companies in this Market
View all 45 →
Aiforia
Aiforia provides AI-powered digital pathology solutions for clinical diagnostics and research. The company offers cloud-based deep learning tools and CE-IVD marked clinical suites for analyzing pathology images across multiple cancer types, serving pathologists, researchers, and diagnostic laboratories worldwide.
Aignostics
Aignostics develops AI-powered pathology solutions for precision medicine, specializing in tumor microenvironment analysis from H&E-stained whole slide images. The company serves life sciences companies and academic researchers with foundation models and custom analytics services.
Aiosyn
Aiosyn develops AI-powered computational pathology software that integrates into standard digital pathology workflows. The company specializes in deep learning solutions for cancer and chronic kidney disease diagnostics, serving clinical laboratories, biopharma, and CROs.
AIxMed
AIxMed develops AI-powered computational cytology platforms for cancer detection and diagnosis. The company's flagship product AIxURO analyzes urine cytology for bladder cancer, with additional platforms in development for thyroid, cervical, and lung cancer screening.
Akoya Biosciences
Akoya Biosciences, now part of Quanterix, provides spatial biology solutions for high-plex tissue analysis. The company develops instruments, assays, and software for spatial proteomics research, enabling researchers to map biomarkers at single-cell resolution in tissue samples.
Caris Life Sciences
Caris Life Sciences is a leading precision medicine company that provides comprehensive molecular profiling for cancer patients. The company combines genomic, transcriptomic, and proteomic data with AI to deliver personalized treatment insights for oncologists and patients.
CellaVision
201-500 employees
CellaVision is a world-leading provider of digital hematology microscopy solutions covering analyzers, instruments, reagents, and software. The company automates workflows in hematology laboratories of all sizes for human and animal blood and body fluid sample analysis.
Clever Culture Systems
Clever Culture Systems develops AI-powered automated microbiology culture plate reading technology for pharmaceutical and clinical laboratories. Their flagship product, APAS Independence, automates the imaging, interpretation, and reporting of microbial growth on culture plates.
Data Accuracy Notice: Company information on HealthAI Central is compiled from public sources and updated regularly. While we strive for accuracy, details such as funding figures, employee counts, and product offerings may change. We recommend verifying critical information directly with the company before making business decisions.